Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 7/20 | 0.34 |
| ▸ | CCKBR | P32239 | 1/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.32 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.32 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.31 |
| ▸ | MC4R | P32245 | 3/20 | 0.30 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.30 |
| ▸ | NPY1R | P25929 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23974299 | 0.95 | FOLH1 (0.38) | FOLH1DGAT1CCKBRSIRT2SIRT1 | |
| SCHEMBL24491129 | 0.89 | FOLH1 (0.35) | FOLH1DGAT1SIRT2SIRT1C3AR1 | |
| SCHEMBL24491139 | 0.86 | CCKBR (0.34) | FOLH1DGAT1CCKBRSIRT2SIRT1 | |
| SCHEMBL24491137 | 0.85 | FOLH1 (0.34) | FOLH1DGAT1CCKBRSIRT2SIRT1 | |
| SCHEMBL23760416 | 0.80 | PCSK9 (0.38) | FOLH1DGAT1SIRT2SIRT1 | |
| SCHEMBL23760412 | 0.80 | PCSK9 (0.38) | FOLH1DGAT1SIRT2SIRT1 | |
| SCHEMBL24451211 | 0.77 | DGAT1 (0.33) | FOLH1DGAT1SIRT2SIRT1 | |
| SCHEMBL24451140 | 0.77 | DGAT1 (0.33) | FOLH1DGAT1SIRT2SIRT1 | |
| SCHEMBL24472556 | 0.77 | FAP (0.32) | FOLH1DGAT1SIRT2SIRT1 | |
| SCHEMBL25100437 | 0.75 | ROCK2 (0.42) | SIRT2SIRT1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220175761-A1 | BI-LIGAND DRUG CONJUGATE AND USE THEREOF | COHERENT BIOPHARMA SUZHOU LTD (CN) | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175761-A1 | BI-LIGAND DRUG CONJUGATE AND USE THEREOF | SLC10A1, CD47, SELPLG | FOLH1 234/4885DGAT1 3656/4885CCKBR 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.